Skip to main content

Table 3 Correlation between clinicopathological factors and the LOH status at the 16q22 minimal locus

From: Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer

Factor Loss of heterozygosity Retention of heterozygosity Total P
Total 22 (51.2%) 21 (48.8%) 43 (100%)  
Age (year)     
≤ 50 7 (43.8%) 9 (56.2%) 16 NS
> 50 15 (55.6%) 12 (44.4%) 27  
Tumor size     
< 2.0 6 (46.2%) 7 (53.8%) 13 NS
≥ 2.0 16 (55.2%) 13 (44.8%) 29  
Not measurable 0 1 1  
Lymph node     
Negative 9 (37.5%) 15 (62.5%) 24 0.084
Positive 11 (64.7%) 6 (45.3%) 17  
Unknown 2 0 2  
Histological grade     
1/2 6 (60.0%) 4 (40.0%) 10 NS
3 14 (50.0%) 14 (50.0%) 28  
Unknown 2 3 5  
Estrogen receptor-α     
Negative 4 (40.0%) 6 (60.0%) 10 NS
Positive 17 (54.8%) 14 (45.2%) 31  
Unknown 1 1 2  
Progesterone receptor     
Negative 2 (18.2%) 9 (81.8%) 11 0.013*
Positive 16 (61.5%) 10 (38.5%) 26  
Unknown 4 2 6  
HER2     
Negative 18 (60.0%) 12 (40.0%) 30  
Positive 2 (20.0%) 8 (80.0%) 10 0.024*
Unknown 2 1 3  
  1. Estrogen receptor-α, progesterone receptor, and human epidermal growth factor (HER) 2 were determined histochemically.
  2. *P < 0.05.